Form 4: Emergent BioSolutions Executive Acquires Shares and Options

A Form 4 filing reveals that Simon C. Lowry, SVP, R&D, CMO of Emergent BioSolutions, acquired shares and stock options on December 15, 2024.

Summary

• Simon C. Lowry, a Senior Vice President at Emergent BioSolutions, acquired 29,482 shares of common stock and 40,499 employee stock options on December 15, 2024.
• The shares were acquired as restricted stock units under the company's Stock Incentive Plan.
• These restricted stock units vest in three annual installments starting the day before the anniversary of the grant date.
• Each restricted stock unit represents the right to receive one share of common stock.
• The employee stock options also vest in three equal installments beginning on the day prior to the anniversary date of the grant.
• The options have an exercise price of $8.48 and expire on December 14, 2031.

Sentiment

Score: 6

Explanation: The document is a routine filing of an executive's stock and option acquisition. It is neither particularly positive nor negative, but indicates standard compensation practices.

Positives

• The acquisition of shares and options by a high-ranking executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry.
• The vesting schedules of three years are also typical for these types of grants.
• The exercise price of $8.48 is specific to Emergent BioSolutions and would need to be compared to other companies in the sector to determine if it is standard.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates executive confidence in the company.

Key Dates

Keywords

Emergent BioSolutions, stock options, restricted stock units, Form 4, insider trading, equity, executive compensation